28.6 C
Vientiane
Tuesday, July 1, 2025
spot_img
Home Blog Page 720

DeepQure Advances Global Clinical Trials for Innovative RDN Technology

SEOUL, South Korea, March 4, 2025 /PRNewswire/ — Breaking Barriers in Hypertension Treatment
DeepQure Inc., a pioneering medical device startup, is revolutionizing the treatment of resistant hypertension with its innovative extravascular (laparoscopic approach) renal denervation (RDN) device, HyperQureTM. Unlike traditional catheter-based RDN systems, HyperQureTM employs a novel approach to achieve more effective and precise sympathetic nerve ablation, minimizing the limitations of existing technologies.

Significant Progress in Global Clinical Trials
DeepQure is actively conducting clinical trials in both South Korea and the United States, demonstrating promising results. In South Korea, seven patients have undergone the procedure, showing meaningful reductions in blood pressure without any adverse events during- or post-operation. The company aims to complete enrollment for its Korean clinical trial within the first quarter of 2025.

In the United States, DeepQure successfully completed its first clinical case on January 17, 2025, at the University of California, Irvine (UC Irvine). The procedure, performed by Dr. Pengbo Jiang, yielded significant blood pressure reductions one month after the operation with no reported complications. The next patient is scheduled for treatment in March, with additional IRB approvals secured from prestigious institutions, including Mayo Clinic and Stanford University.

DeepQure’s U.S. clinical trial spans six leading university hospitals, with Institutional Review Board (IRB) approvals finalized. The company plans to enroll 15 patients in the first half of 2025, with the ultimate goal of initiating a pivotal study by year-end to establish the safety and efficacy of HyperQureTM.

Expanding Indications: Atrial Fibrillation (Afib) Treatment
Beyond hypertension, DeepQure is expanding its RDN technology to address atrial fibrillation (Afib), one of the most common cardiac arrhythmias. The company has submitted an application to South Korea’s Ministry of Food and Drug Safety (MFDS) to initiate clinical trials for Afib treatment.

Currently, Pulmonary Vein Isolation (PVI) is the standard treatment for Afib, but its major drawback is a high recurrence rate of approximately 30-50%. DeepQure’s RDN technology is expected to enhance the effectiveness of PVI procedures by reducing recurrence rates, offering a breakthrough solution in a field where drug therapy has shown limited success.

Shaping the Future of Cardiovascular Care
With its pioneering technology, strong clinical momentum, and expansion into new indications, DeepQure is positioning itself as a leader in the medical device industry. As the global RDN market is projected to grow from $1.3 billion in 2024 to $10.3 billion by 2031 (CAGR 34.4%), DeepQure’s innovations stand at the forefront of next-generation hypertension and cardiac arrhythmia treatments.

As the company continues to advance its clinical programs and regulatory milestones, DeepQure remains committed to setting a new standard in cardiovascular intervention, bringing life-changing solutions to patients worldwide.

Contact: gwnoh@deepqure.com 

President Trump Proposes CoinDesk Large Cap Select Index (“CoinDesk 5”) Components for U.S. Crypto Strategic Reserve

NEW YORK, March 4, 2025 /PRNewswire/ — The U.S. digital asset market reached a pivotal milestone with President Trump’s announcement of a proposed U.S. Crypto Strategic Reserve, which includes the same assets tracked by the CoinDesk Large Cap Select Index (“CoinDesk 5”). The President’s support reinforces growing U.S. institutional adoption of digital assets, providing a clear signal to markets that regulatory standards and investment infrastructure are maturing.

“The assets proposed for the President’s Crypto Reserve mirror the constituents of the CoinDesk 5, highlighting CoinDesk Indices’ position as the industry standard for digital asset benchmarks, ” said Alan Campbell, President of CoinDesk Indices. “This development strengthens confidence in diversified digital asset investment products and aligns with the broader trend of accelerating market adoption we’re seeing.”

With approximately $750 million in assets linked to the CoinDesk 5, the index has established itself as a trusted benchmark for investment products tracking the largest digital assets by market capitalization and liquidity. Financial institutions leveraging the index include Grayscale Investments, whose large cap fund was launched in February 2018. Other linked-products include Luno Large Cap Bundle, Lyons CoinDesk Large Cap Select Index SMA and BitGo Platform for Wealth Management.

Grayscale operates a publicly-traded investment vehicle in the US that holds the identical assets included in the recently announced U.S. Crypto Strategic Reserve. “Grayscale’s Digital Large Cap Fund is an index fund that has been operating for over 7 years with the support of the CoinDesk Index team, currently trades under ticker GDLC, and was most recently priced at a discount of over 10% compared to the fair value of its holdings, Bitcoin, Ethereum, XRP, Solana and Cardano,” said Peter Mintzberg, CEO, Grayscale.   

Beyond the CoinDesk 5, investors seeking broader market exposure are increasingly turning to the CoinDesk 20 Index, the most traded diversified digital asset benchmark globally, with nearly $14 billion in accumulated futures and options volume. CoinDesk 20 serves as a high-liquidity reference point for institutional investors managing digital asset portfolios and is available through over a dozen investment vehicles globally.

“As digital assets integrate further into the global financial system, we anticipate increased demand for risk management and hedging tools,” added Campbell. “The U.S. administration’s embrace of crypto signals the normalization of digital assets within mainstream financial markets, bringing them closer to traditional asset classes.”

For more information on the index visit our website.

About CoinDesk Indices
Since 2014, CoinDesk Indices has been at the forefront of the digital asset revolution, empowering investors globally. A portfolio company of the Bullish Group, our indices form the foundation of the world’s largest digital asset products. CoinDesk Indices is regulated in the UK by the Financial Conduct Authority and offers products across multi-asset indices, reference rates, and strategies. Flagships such as the CoinDesk Bitcoin Price Index and the CoinDesk 20 Index set the industry standard for measuring, trading, and investing in digital assets. With tens of billions of dollars in benchmarked assets, CoinDesk Indices is a trusted partner.  

Disclaimer 
CoinDesk is a portfolio company of the Bullish Group. CoinDesk Indices, Inc., including CC Data Limited, its affiliate which performs certain outsourced administration and calculation services on its behalf (collectively, “CoinDesk Indices”), does not sponsor, endorse, sell, promote, or manage any investment offered by any third party that seeks to provide an investment return based on the performance of any index. CoinDesk Indices is neither an investment adviser nor a commodity trading advisor and makes no representation regarding the advisability of making an investment linked to any CoinDesk Indices index. CoinDesk Indices does not act as a fiduciary. A decision to invest in any asset linked to a CoinDesk Indices index should not be made in reliance on any of the statements set forth in this document or elsewhere by CoinDesk Indices. All content displayed here or otherwise used in connection with any CoinDesk Indices index (the “Content”) is owned by CoinDesk Indices and/or its third-party data providers and licensors, unless stated otherwise by CoinDesk Indices. CoinDesk Indices does not guarantee the accuracy, completeness, timeliness, adequacy, validity, or availability of any of the Content. CoinDesk Indices is not responsible for any errors or omissions, regardless of the cause, in the results obtained from the use of any of the Content. CoinDesk Indices does not assume any obligation to update the Content following publication in any form or format. © 2025 CoinDesk Indices, Inc. All rights reserved. 

Digital Garden Tokyo to Feature Unprecedented Speaker Lineup and Over 80 Companies Represented by C-Suite Delegations at Japan’s First Global-Scale Digital Infrastructure Summit

TOKYO, March 4, 2025 /PRNewswire/ — With just two weeks until the highly anticipated Digital Garden Tokyo, excitement is building for Japan’s inaugural global-scale digital infrastructure summit. Taking place on March 17-18, 2025, at Toranomon Hills Forum, the event will bring together over 80 companies, primarily represented by C-suite delegations, including leading investment firms, operators, hyperscalers, cloud providers, end users, and industry leaders. This pivotal gathering will provide a broad perspective on the future of digital infrastructure.

The speaker lineup includes Yasutoshi Nishimura, member of the House of Representatives and former Minister of Economy, Trade, and Industry (METI), who will share insights into Japan’s digital infrastructure strategy and global positioning.

A highlight of the summit will be the Government Panel, featuring senior leaders from Japan’s key policymaking bodies, offering a unified view of digital infrastructure policy. Panelists include:

  • Sachio Muto, Director, International and Digital Policy (IDP) Division, City Bureau, MLIT
  • Kazuhiro Wakatsuki, Chief Director, Digital Agency
  • Takuya Watanabe, Director, Software & Information Service Industry Strategy Office, METI

These experts will provide valuable perspectives on Japan’s digital policies, future strategies, and collaborative efforts shaping the sector.

The summit will also feature senior executives and regional leaders from major digital infrastructure organizations. Confirmed speakers include leaders from:

Ada Infrastructure, AirTrunk, COLT DCS, Cushman & Wakefield, CyrusOne, DigitalBridge, DigitalEdge, Gaw Capital, Greenberg Traurig, Kansai Electric, Mercari, Morrison Foerster, PGIM, SMBC, SoftBank Group, ST Telemedia, University of Tokyo, and more.

These executives will discuss key industry trends, innovations, and strategies driving the sector forward.

The summit’s Gala on the first evening will gather top stakeholders to foster collaboration, build partnerships, and drive transactions in the digital infrastructure space.

Bringing together top executives, thought leaders, and policymakers, the event will create a dynamic environment for discussions on pressing challenges and opportunities, from government policy to investment and technology.

“We’re thrilled to convene such an exceptional group of leaders across the digital infrastructure sector,” said Daniel Cox, Executive Chairman of Digital Garden Tokyo. “With C-suite executives, government representatives, and industry innovators in one place, this summit will foster collaboration and shape the future of digital infrastructure in Japan and across the region.”

Digital Garden Tokyo promises unparalleled networking, cutting-edge insights, and critical discussions. Don’t miss this key moment in Japan’s digital infrastructure evolution.

For details and registration, please visit www.digitalgarden.co.jp.

CONTACT: media@digitalgarden.co.jp

Raziel and Fosun Pharma (by JuveStar an affiliate company of Fosun Pharma) Initiate Phase 3 Registration Trial in China for Submental Fat Reduction (“double chin”)

REROVOT, Israel, March 4, 2025 /PRNewswire/ — Raziel Therapeutics, a pharmaceutical company developing next-generation novel prescription products for the medical aesthetics market, announces phase 3 study initiation in China for the treatment of fat reduction in the submental area. Submental fat (SMF) reduction is the first indication for RZL-012 among many potential aesthetic focal fat reduction treatments for body shaping.

RZL-012 is an injectable lipolytic drug being developed for the reduction of unwanted submental fat (“double-chin”) or fat in other body areas, in adults. The compound is injected subcutaneously into submental fat tissue in 1-2 injection sessions by trained physicians and destroys fat cells, resulting in fat volume reduction and improved appearance of the injected area. 

Raziel Therapeutics and Tianjin JuveStar Biotech Co., Ltd., (JuveStar), a company invested and incubated by the venture capital arm of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma, stock code: 600196.SH, 02196.HK), partnered with Raziel Therapeutics to develop RZL-012 and JuveStar holds the commercial rights for RZL-012 in Greater China. A phase 3 study will be initiated in China during the upcoming few weeks. JuveStar will be responsible for conducting the phase 3 study, while Raziel will be responsible for manufacturing the drug substance and finished drug product for the clinical activities in China. The product is expected to be launched in China during 2027. “The initiation of phase 3 study in the China market is a significant progress, we believe that RZL 012 will be a lead drug for focal fat reduction in China” said Alon Bloomenfeld Founder and CEO of Raziel therapeutics. 

Fosun Pharma is one of the leading healthcare companies in China, with expertise and access to both the aesthetic and therapeutic markets. The collaboration will enrich Fosun Pharma’s pipeline in the field of medical aesthetics and provide more options for the unmet clinical needs. The market for focal reduction of resistant fat based therapies, has high potential and is complementary to the widespread use of weight loss therapies. The benefit of using RZL-012 is its ability to target focal or localized unwanted fat with only 1-2 treatment cycles.

About Submental Fullness

Submental fullness is a common yet undertreated condition that can detract from an otherwise balanced and harmonious facial appearance – leading to an older and heavier look. Submental fullness can affect adults – both women and men – of all ages, weights and genders. Influenced by multiple factors including aging and genetics, submental fullness is often resistant to diet and exercise.

About RZL – 012

RZL-012 is a novel small molecule entity formulated with no human and no animal related components. When injected into subcutaneous fat, RZL-012 destroys fat cells and reduces fat volume. Once destroyed, those cells can no longer store or accumulate fat.

About Fosun Pharma:

Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (“Fosun Pharma”; stock code: 600196.SH, 02196.HK) is a global innovation-driven pharmaceutical and healthcare industry group. Fosun Pharma directly operates businesses including pharmaceuticals, medical devices, medical diagnosis, and healthcare services. As a shareholder of Sinopharm Co., Ltd., Fosun Pharma expands its areas in the pharmaceutical distribution and retail business.

Fosun Pharma is patient-centered and unmet clinical needs-oriented. Through diversified and multi-level cooperation models such as independent research and development, cooperative development, license-in, and industrial investment, the company continues to enrich its innovative product pipeline and focus on differentiated product R&D with high-tech barriers, to continuously enhance the value of its pipeline. Fosun Pharma’s innovative products focus on core therapeutic areas such as solid tumors, hematologic tumors and immunity inflammation. It also strengthens core technology platforms such as antibodies/ADC, cell therapy, and small molecules.

Guided by the 4IN strategy (Innovation, Internationalization, Intelligentization, and Integration), Fosun Pharma adheres to the business philosophy of “Innovation for Good Health”, continues to promote innovative transformation, actively deploys internationalization, strengthens business focus by product lines, promotes integrated operations and efficiency improvement, and is dedicated to being the global leading integrator of pharmaceutical and healthcare innovation.

For more information, please visit: www.fosunpharma.com.

About Raziel Therapeutics.

Raziel Therapeutics is an emerging Israeli based pharmaceutical leader developing a disruptive technology for the treatment of aesthetic indications. Raziel has developed a unique proprietary compound by obtaining a License from the Hebrew university.  The company’s lead compound, RZL-012, is in phase 2 or 3 clinical development for a broad range of aesthetic indications. More information on Raziel Therapeutics may be found at https://raziel-therapy.com/

Contact:
Alon Bloomenfeld
alon@raziel-therapy.com
+972542325070

Binance Supports Global Fintech Institute to Advance Fintech Education in the AI & Crypto Era

TOKYO, March 4, 2025 /PRNewswire/ — Binance, the global blockchain ecosystem behind the world’s largest cryptocurrency exchange, has announced its sponsorship and strategic support for the Global Fintech Institute (GFI) to advance fintech education, professional development and innovation. This collaboration aims to equip professionals with the skills needed to thrive in an era defined by artificial intelligence (AI), blockchain, and evolving financial regulations.

Empowering the Fintech Workforce for a Digital Future

As part of this initiative, Binance is excited to sponsor over 500 scholarships for GFI’s latest course, Foundation in Crypto Regulation and Compliance. The course is catered for professionals in regulatory bodies, financial institutions, and compliance roles, especially those with a passion and curiosity for crypto.

Designed by leading industry experts and academics, this 16-hour online program provides regulators and compliance professionals with a comprehensive understanding of blockchain, cryptocurrency, and financial regulations. Participants will also gain hands-on insights into numerous important areas such as AML/KYC compliance and financial crime prevention, blockchain forensics and cross-border regulatory frameworks, RegTech solutions, and more. By the end of the course, attendees will be well-equipped to tackle compliance challenges, mitigate risks, and adapt to the evolving crypto landscape.

Interested professionals can apply for the scholarship at: https://share.hsforms.com/2LlwvBcnnTRGy1PXrfnzKCg5nir0

Importance of Fintech Education in a Transformative Era

Through this strategic collaboration, Binance and GFI aim to equip professionals with expertise in AI-driven finance and digital assets, develop fintech training programs, advance research, host industry events, and enhance global fintech literacy.

Richard Teng, CEO of Binance, commented on the partnership: “We are thrilled to join forces with the Global Fintech Institute to advance fintech education in this transformative era of AI and cryptocurrency. Education plays a crucial role in closing the knowledge gap for blockchain and crypto, just as it has for other emerging technologies in the past. Today’s announcement underscores Binance’s commitment to fostering innovation, enhancing regulatory compliance, and ensuring that the global fintech workforce is future-ready. With the ever-rising interest and popularity of crypto, we are certain that crypto-focused courses like these would be in high demand, and we look forward to welcoming interested applicants.”

Professor David Lee, Founding Chairman at GFI, added: “As AI, blockchain, and digital assets continue to transform the financial landscape, there is an urgent need for structured fintech education and informed policy discussions. The rapid pace of technological advancement demands that professionals, regulators, and institutions stay ahead of emerging trends to ensure financial stability, security, and innovation-driven growth. Binance’s generous support allows us to expand our educational programs, conduct critical research, and foster industry-wide collaboration. This partnership enables us to bridge the knowledge gap between traditional finance and digital innovations, equipping professionals with the expertise to navigate regulatory challenges, harness new opportunities, and drive responsible adoption of cutting-edge financial technologies.”

The Policy Shift & Its Impact on Fintech

The growing political endorsement of digital assets in many key markets globally signals a significant policy shift that could accelerate institutional adoption, regulatory clarity, and the integration of blockchain technology into mainstream finance. If pro-crypto policies gain traction, we could see:

  • More financial institutions embracing Bitcoin, stablecoins, and tokenized assets.
  • Regulatory clarity attracting global investments into fintech startups and digital finance.
  • AI-powered DeFi and blockchain-based financial services gaining wider acceptance, transforming traditional banking.

This partnership between Binance and GFI ensures that compliance and regulation professionals are well-equipped to capitalize on these emerging opportunities by providing cutting-edge training, research, and thought leadership.

The collaboration between Binance and GFI was first announced at GFTN Forum, Japan 2025. Both Binance and GFI are proud members and partners of the GFTN network.

About Binance

Binance is a leading global blockchain ecosystem behind the world’s largest cryptocurrency exchange by trading volume and registered users. Binance is trusted by more than 260 million people in 100+ countries for its industry-leading trading engine speed, protections for investors, and unmatched portfolio of digital asset products and offerings from trading and finance to education, research, social good, payments, institutional services, and Web3 features. Binance is devoted to building an inclusive crypto ecosystem to increase the freedom of money and financial access for people around the world with crypto as the fundamental means.

For more information, visit: https://www.binance.com

About Global Fintech Institute

Global Fintech Institute (GFI) is a not-for-profit think tank and certification body dedicated to advancing fintech education, fostering meaningful collaboration, and promoting professional excellence across regulatory bodies, corporations, and academic institutions. Headquartered in Singapore, GFI tackles key challenges in the fintech landscape through rigorous research, insightful whitepapers, and thought leadership discussions which influence policy and set industry standards.

Analytic Edge Now a Certified Partner in APAC for Google’s Meridian Marketing Mix Modelling (MMM) Platform

SINGAPORE, March 4, 2025 /PRNewswire/ — Analytic Edge (a C5i company), a leading provider of marketing and sales analytics solutions, announced that it is now a certified partner in APAC for Google’s Meridian Marketing Mix Modelling (MMM) platform. Meridian is an open-source MMM platform built by Google to help advertisers measure the impact of their marketing spends on sales and make smarter, data-driven decisions on marketing strategy and budgets.

For the Meridian partnership, Analytic Edge will serve as a consulting and modelling partner to help Google’s advertisers develop MMMs using Meridian. This is particularly useful for advertisers as they can leverage Analytic Edge’s expertise gained from delivering 3000+ MMMs globally over the past 3 years across multiple domains. Advertisers can also tap into a ready pool of Analytic Edge’s data scientists and analysts who are certified on Meridian.

Analytic Edge has worked closely as a Measurement Partner to Google for several years, including delivering multiple MMMs for its own advertisers. The MMMs were delivered using Analytic Edge’s always-on MMM platform, Demand Drivers.

Commenting on the partnership, Santosh Nair, Co-Founder and Director, Analytic Edge, said, “Analytic Edge is excited to apply our extensive MMM experience and to partner with Google on Meridian. Meridian integrates technical innovations to assess the indirect impact of search on marketing channels in the consumer journey. It enhances the measurement of “Reach” and “Frequency” for YouTube campaigns, helping advertisers with campaign planning. The seamless integration with Google MMM Data Platform boosts productivity in data processing and improves the accuracy of the data used in the model. Our collaboration on Meridian will help advertisers better understand the interactions between channels and improve their campaign strategies.”

About Analytic Edge

Analytic Edge, a part of C5i, is a global analytics company that leverages technology and advanced analytics to help companies make data-based marketing decisions. The company’s flagship platform Analytic Edge Qube offers a suite of marketing analytics solutions with a Software as a Service (SaaS) model. The solutions include Demand Drivers, SynTest, PriceSense and PowerView. Analytic Edge works with clients across industry verticals such as e-commerce, mobile apps, gaming, consumer packaged goods, retail, automotive and many others. The company has a presence in Singapore, India, US, Mexico, Brazil, UK, Switzerland, China, Japan, South Korea, UAE and Australia. For more information, visit www.analytic-edge.com 

Media Contact:

Megha Chaudhry

Vice President

Global Head of Marketing & Alliance Management, C5i

O: +1 (425) 615 7474 | E:  megha.chaudhry@c5i.ai

 

 

 

Raziel and Fosun Pharma (by JuveStar an affiliate company of Fosun Pharma) Initiate Phase 3 Registration Trial in China for Submental Fat Reduction (“double chin”)

REROVOT, Israel, March 4, 2025 /PRNewswire/ — Raziel Therapeutics, a pharmaceutical company developing next-generation novel prescription products for the medical aesthetics market, announces phase 3 study initiation in China for the treatment of fat reduction in the submental area. Submental fat (SMF) reduction is the first indication for RZL-012 among many potential aesthetic focal fat reduction treatments for body shaping.

RZL-012 is an injectable lipolytic drug being developed for the reduction of unwanted submental fat (“double-chin”) or fat in other body areas, in adults. The compound is injected subcutaneously into submental fat tissue in 1-2 injection sessions by trained physicians and destroys fat cells, resulting in fat volume reduction and improved appearance of the injected area. 

Raziel Therapeutics and Tianjin JuveStar Biotech Co., Ltd., (JuveStar), a company invested and incubated by the venture capital arm of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma, stock code: 600196.SH, 02196.HK), partnered with Raziel Therapeutics to develop RZL-012 and JuveStar holds the commercial rights for RZL-012 in Greater China. A phase 3 study will be initiated in China during the upcoming few weeks. JuveStar will be responsible for conducting the phase 3 study, while Raziel will be responsible for manufacturing the drug substance and finished drug product for the clinical activities in China. The product is expected to be launched in China during 2027. “The initiation of phase 3 study in the China market is a significant progress, we believe that RZL 012 will be a lead drug for focal fat reduction in China” said Alon Bloomenfeld Founder and CEO of Raziel therapeutics. 

Fosun Pharma is one of the leading healthcare companies in China, with expertise and access to both the aesthetic and therapeutic markets. The collaboration will enrich Fosun Pharma’s pipeline in the field of medical aesthetics and provide more options for the unmet clinical needs. The market for focal reduction of resistant fat based therapies, has high potential and is complementary to the widespread use of weight loss therapies. The benefit of using RZL-012 is its ability to target focal or localized unwanted fat with only 1-2 treatment cycles.

About Submental Fullness

Submental fullness is a common yet undertreated condition that can detract from an otherwise balanced and harmonious facial appearance – leading to an older and heavier look. Submental fullness can affect adults – both women and men – of all ages, weights and genders. Influenced by multiple factors including aging and genetics, submental fullness is often resistant to diet and exercise.

About RZL – 012

RZL-012 is a novel small molecule entity formulated with no human and no animal related components. When injected into subcutaneous fat, RZL-012 destroys fat cells and reduces fat volume. Once destroyed, those cells can no longer store or accumulate fat.

About Fosun Pharma:

Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (“Fosun Pharma”; stock code: 600196.SH, 02196.HK) is a global innovation-driven pharmaceutical and healthcare industry group. Fosun Pharma directly operates businesses including pharmaceuticals, medical devices, medical diagnosis, and healthcare services. As a shareholder of Sinopharm Co., Ltd., Fosun Pharma expands its areas in the pharmaceutical distribution and retail business.

Fosun Pharma is patient-centered and unmet clinical needs-oriented. Through diversified and multi-level cooperation models such as independent research and development, cooperative development, license-in, and industrial investment, the company continues to enrich its innovative product pipeline and focus on differentiated product R&D with high-tech barriers, to continuously enhance the value of its pipeline. Fosun Pharma’s innovative products focus on core therapeutic areas such as solid tumors, hematologic tumors and immunity inflammation. It also strengthens core technology platforms such as antibodies/ADC, cell therapy, and small molecules.

Guided by the 4IN strategy (Innovation, Internationalization, Intelligentization, and Integration), Fosun Pharma adheres to the business philosophy of “Innovation for Good Health”, continues to promote innovative transformation, actively deploys internationalization, strengthens business focus by product lines, promotes integrated operations and efficiency improvement, and is dedicated to being the global leading integrator of pharmaceutical and healthcare innovation.

For more information, please visit: www.fosunpharma.com.

About Raziel Therapeutics.

Raziel Therapeutics is an emerging Israeli based pharmaceutical leader developing a disruptive technology for the treatment of aesthetic indications. Raziel has developed a unique proprietary compound by obtaining a License from the Hebrew university.  The company’s lead compound, RZL-012, is in phase 2 or 3 clinical development for a broad range of aesthetic indications. More information on Raziel Therapeutics may be found at https://raziel-therapy.com/

Contact:
Alon Bloomenfeld
alon@raziel-therapy.com
+972542325070

WuXi Biologics Launches EffiX™ Microbial Expression Platform to Boost Recombinant Protein and Plasmid DNA Production

–          EffiX™ is designed to meet the industry’s demand for a high-yield, stable, and non-lysogenic E. coli expression system. It serves as a comprehensive solution for the development and manufacturing of non-monoclonal antibody (non-mAb) recombinant proteins and plasmid DNA for clients across the globe

–          EffiX™ delivers high-yield production across multiple modalities, achieving titers of over 15 g/L for non-mAb recombinant proteins and over 1 g/L for plasmid DNA

HANGZHOU, China, March 4, 2025 /PRNewswire/ — WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the launch of its innovative technology platform, EffiX™, a proprietary E. coli expression system engineered to deliver high yield and exceptional stability in the production of recombinant proteins and plasmid DNA.

The global market for microbial-derived products and intermediates is expanding rapidly, driven by increasing demand for smaller complex biomolecules — such as antibody fragments, nanobodies, enzymes, cytokines, various antigens, polypeptides, and plasmid DNA (pDNA) — all of which present significant opportunities for the development of next-generation therapies. To address the challenges in producing these biomolecules, WuXi Biologics has introduced the EffiX™ platform, which enables the development and manufacturing of microbial-derived biologics with high yield, consistent quality, as well as superior stability and scalability. The EffiX™ platform achieves titers exceeding 15 g/L for non-mAb recombinant proteins and over 1 g/L for plasmid DNA.

With streamlined processes tailored to accommodate a diverse range of project requirements from research through commercial manufacturing, the EffiX™ platform accelerates the advancement of innovative biotherapeutics for global partners by offering a comprehensive and cost-effective Chemistry, Manufacturing, and Controls (CMC) strategy.

Dr. Chris Chen, CEO of WuXi Biologics, commented, “We are excited to upgrade our microbial solutions with the innovative EffiX™ platform, which offers our clients exceptional productivity and product quality, along with scalability and flexibility at every stage of development. WuXi Biologics’ continual launching of new technology platforms stems from our drive to push boundaries and foster innovation – all with the goal of enabling our global partners to accelerate the delivery of more high-quality and affordable biologics to patients worldwide.”

The EffiX™ platform is an integral component of a broader integrated technology platform at WuXi Biologics, which is predicated on microbial expression systems. This comprehensive platform encompasses early-stage research, CMC development, and GMP manufacturing, facilitating faster, more efficient, and cost-effective manufacturing processes for various modalities in the realm of next-generation therapies.

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.

With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of December 31, 2024, WuXi Biologics is supporting 817 integrated client projects, including 21 in commercial manufacturing (excluding COVID CMO projects).

WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to be an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.

For more information about WuXi Biologics, please visit: www.wuxibiologics.com.

Contacts

Business
info@wuxibiologics.com

Media
PR@wuxibiologics.com